Document:

Amended and Restated Employment Agreement - Paul T. Quinlan

 Exhibit 10.22 

 

 

 May 19, 2011 
 Paul T. Quinlan

 c/o Solazyme, Inc. 
 225 Gateway Boulevard 

South San Francisco, CA 94080 
 Dear Paul, 

This amended and restated employment letter confirms your position with Solazyme, Inc. (“Solazyme”) as General Counsel &
Secretary. Your annual base salary (which, effective as of January 1, 2011 is $300,000), is paid semi-monthly according to our normal payroll schedule and subject to standard deductions and withholding. Your annual target bonus as of the date
of this letter is equal to 40% of your annual base salary. Your actual bonus, if any, will be determined by the Solazyme compensation committee, in its sole discretion, based upon its evaluation of your performance, Solazyme’s performance, and
any other considerations it deems relevant. As an employee, you are eligible to receive certain employee benefits as listed in Solazyme’s benefit summary, which is available to you on request. You should note that Solazyme may modify job
titles, salaries, target bonuses and benefits from time to time as it deems necessary. 
 You are eligible for equity awards that may be
made to you from time-to-time, subject to the approval of the Solazyme compensation committee, in its sole discretion. 
 Your employment
with Solazyme is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, Solazyme is free to conclude its employment relationship with you at any time,
with or without cause, and with or without notice. 
 You agree that, during the term of your employment with Solazyme, you will not
engage in any other employment, occupation, consulting or other business activity directly related to the business in which Solazyme is now involved or becomes involved during the term of your employment, nor will you engage in any other activities
that conflict with your obligations to our company. Similarly, you agree not to bring any third party confidential information to Solazyme, including that of any former employers. 

As a condition of your employment, you were required to sign and comply with a Proprietary Information and Inventions Agreement (“Inventions
Agreement”), which requires, among other provisions, the assignment of patent rights to any invention made during your employment at Solazyme, and non-disclosure of Solazyme proprietary information. 

Solazyme will enter into its standard Indemnification Agreement for executive officers with you. Furthermore, during your service as an officer of
Solazyme, you will be covered by Solazyme’s directors and officers (D&O) liability insurance as in effect from time to time. 

You hereby authorize Solazyme to use, reuse, and to grant others the right to use and reuse your name, and biographical information, as well as any
photograph, likeness (including caricature), and voice recording generated during your employment with Solazyme that relates to Solazyme, and any reproduction or simulation thereof, in any media now known or hereafter developed (including, but not
limited to film, video and digital or other electronic media), both during and after your employment, for whatever purposes Solazyme deems necessary for its business. 

 
  
 Solazyme, Inc., 225 Gateway Boulevard, South San Francisco, California 94080 

 Paul T. Quinlan 
 Page
2 
 May 19, 2011 
 It is important that
you agree with us that this offer letter constitutes the entire statement with respect to the terms of your employment at Solazyme and that there are no oral agreements or understandings or any other written agreements that directly or indirectly
affect the employment relationship between us and you. If there are any, please do not sign this letter until you have consulted with me and the parties have either modified this letter to state those understandings or agreed that there are no such
understandings or agreements. This document is fully integrated with respect to the matters described herein and supersedes in its entirety the previous Employment Offer Letter dated April 23, 2010. Notwithstanding the foregoing, nothing herein
modifies the Solazyme equity awards you have previously been granted. In addition, you are eligible for Solazyme’s Executive Severance and Change in Control Plan, which has been provided to you separately. Your participation in that plan is
currently as a Group C participant. 
 We are very excited about your continued participation in the Solazyme team and hope you will
continue to find this to be a challenging, exciting and enjoyable work environment. Please sign and date this letter and return it to Lisa Roslund in the Human Resources Department. 
 Sincerely, 
 /s/ Harrison Dillon 
 Harrison Dillon 
 President 
 Accepted and agreed: 
  

	
	
	    /s/ Paul T. Quinlan
	Paul T. QuinlanUnderwriting Agreement

 Exhibit 4.1 
 EXECUTION VERSION 
 UNDERWRITING AGREEMENT 

May 16, 2011 
 Texas Instruments
Incorporated 
 12500 TI Boulevard 

Dallas, Texas 75266-0199 
 Dear Sirs:

 We (the “Underwriters”) understand that Texas Instruments Incorporated, a Delaware corporation (the
“Company”), proposes to issue and sell $1,000,000,000 principal amount of the Floating Rate Notes due 2013, $500,000,000 principal amount of the 0.875% Notes due 2013, $1,000,000,000 principal amount of the 1.375% Notes due 2014 and
$1,000,000,000 principal amount of the 2.375% Notes due 2016 (the “Offered Securities”) identified in Schedule I hereto, as more fully described in the Time of Sale Prospectus. The Offered Securities will be issued pursuant to an
Indenture to be dated as of May 23, 2011, between the Company and U.S. Bank National Association, as trustee. 
 Subject to
the terms and conditions set forth herein or incorporated by reference herein, the Company agrees to sell and the Underwriters agree to purchase, severally and not jointly, at the respective purchase prices set forth in Schedule I hereto, the
principal amount of the Offered Securities set forth opposite their respective names in Schedule II hereto. For purposes of this Agreement, “Applicable Time” means 5:00 p.m. (New York time) on the date hereof. 

Payment of the purchase price for the Offered Securities shall be made to the Company by Federal funds wire transfer against delivery of
the Offered Securities in book-entry form to the Manager through the facilities of The Depository Trust Company for the respective accounts of the Underwriters. Such payment and delivery and all documents with respect to the purchase of the Offered
Securities shall be delivered by the parties at the offices of counsel for the Underwriters at 10:00 A.M. (New York time) on May 23, 2011, or at such other time, not later than May 31, 2011, as shall be designated by the Manager.

 All the provisions contained in the document entitled Texas Instruments Incorporated Underwriting Agreement Standard
Provisions dated May 16, 2011 (the “Standard Provisions”), a copy of which is attached hereto, are herein incorporated by reference in their entirety and shall be deemed to be a part of this Agreement to the same extent as if
such provisions had been set forth in full herein, except that (i) if any term defined in the Standard Provisions is otherwise defined herein, the definition set forth herein shall control, (ii) all references in the Standard Provisions to
a type of security that is not an Offered Security and the related representations, warranties, opinions given or to be given in respect thereof and the related covenants, conditions and other obligations relating thereto shall not be deemed to be a
part of this Agreement, (iii) all references in the Standard Provisions to a type of agreement that has not been entered into in connection with the transactions contemplated hereby shall not be deemed to be a part of this Agreement and
(iv) the term “Manager,” as used therein, shall, for purposes of this Agreement, 

 
mean Morgan Stanley & Co. Incorporated, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Citigroup Global Markets Inc., whose authority
hereunder may be exercised by them jointly. 
 For purposes of Section III(e) of the Standard Provisions, references to the
“Company” shall be deemed to include both Texas Instruments Incorporated and National Semiconductor Corporation and references to certain financial information shall include financial information of National Semiconductor Corporation
contained in the Texas Instruments Incorporated current report on Form 8-K filed with the Commission on May 16, 2011. 

  
 2 

 Please confirm your agreement by having an authorized officer sign a copy of this Agreement
in the space set forth below. This Agreement may be signed in any number of counterparts with the same effect as if the signatures thereto and hereto were upon the same instrument. 

 

			
	Very truly yours,
	
	On behalf of themselves and the several Underwriters listed in Schedule II hereto
	
	Morgan Stanley & Co. Incorporated

  

			
	By:	 	 /s/ Yurij Slyz

		 	 Name: Yurij Slyz

		 	 Title: ED

 

			
	 J.P. Morgan Securities LLC

		
	By:	 	 /s/ Robert Bottomedi

		 	 Name: Robert Bottomedi

		 	 Title: Vice President

  
 3 

			
	Accepted as of the date written above:
	
	    TEXAS INSTRUMENTS INCORPORATED
		
	    By:	 	 /s/ Charles Tobin

		 	 Name: Charles D. Tobin

		 	 Title: Vice President and Treasurer

  
 4 

 SCHEDULE I 
 TO UNDERWRITING AGREEMENT 
 Filed Pursuant to Rule 433 

Registration No. 333-165045 
 Issuer Free Writing Prospectus dated May 16, 2011 
 Relating to
Preliminary Prospectus Supplement dated May 16, 2011 
 TEXAS INSTRUMENTS INCORPORATED 

Pricing Term Sheet 
 Floating Rate Notes due 2013 
  

			
	Issuer:	  	Texas Instruments Incorporated (“TI”)
		
	Principal Amount:	  	$1,000,000,000
		
	Maturity:	  	May 15, 2013
		
	Coupon:	  	Three-month USD LIBOR plus 0.18%
		
	Price to Public:	  	100% of principal amount
		
	Interest:	  	Interest will be payable quarterly in arrears on February 15, May 15, August 15 and November 15, commencing on August 15, 2011. Interest will be determined as set forth under
“Description of the Notes—Interest on Floating Rate Notes” in the preliminary prospectus supplement dated May 16, 2011 to the prospectus dated February 24, 2010, and reset quarterly. The initial Interest Determination Date will be May
19, 2011.
		
	Day Count Convention:	  	Actual Days Elapsed/360
		
	Proceeds (before expenses) to TI:	  	$998,500,000
		
	Trade Date:	  	May 16, 2011
		
	Settlement Date:	  	May 23, 2011 (T+5)
		
	Denominations:	  	$2,000 and multiples of $1,000 thereafter
		
	CUSIP/ISIN:	  	882508 AS3 / US882508AS30
		
	Ratings:	  	 Moody’s: A1
 S&P:
A+

		
	Joint Book-Running Managers:	  	 Morgan Stanley & Co. Incorporated
 J.P. Morgan Securities LLC
 Merrill Lynch, Pierce, Fenner & Smith Incorporated

Citigroup Global Markets Inc.

  
 5 

 0.875% Notes due 2013 

 

			
		
	Issuer:	  	Texas Instruments Incorporated (“TI”)
		
	Principal Amount:	  	$500,000,000
		
	Maturity:	  	May 15, 2013
		
	Coupon:	  	0.875%
		
	Price to Public:	  	99.953% of principal amount
		
	Interest Payment Dates:	  	May 15 and November 15, commencing November 15, 2011
		
	Day Count Convention:	  	30/360
		
	Proceeds (before expenses) to TI:	  	$499,015,000
		
	Benchmark Treasury:	  	0.625% due April 30, 2013
		
	Spread to Benchmark Treasury:	  	37.5 basis points
		
	Yield to Maturity:	  	0.899%
		
	Benchmark Treasury Yield:	  	0.524%
		
	Make-Whole Call:	  	At any time at a discount rate of Treasury plus 5 basis points
		
	Special Mandatory Redemption:	  	At 101%, if TI’s merger with National Semiconductor Corporation has not closed by April 30, 2012, or such earlier date as the merger agreement is terminated
		
	Trade Date:	  	May 16, 2011
		
	Settlement Date:	  	May 23, 2011 (T+5)
		
	Denominations:	  	$2,000 and multiples of $1,000 thereafter
		
	CUSIP/ISIN:	  	882508 AP9 / US882508AP90
		
	Ratings:	  	 Moody’s: A1
 S&P:
A+

		
	Joint Book-Running Managers:	  	 Morgan Stanley & Co. Incorporated
 J.P. Morgan Securities LLC
 Merrill Lynch, Pierce, Fenner & Smith Incorporated

Citigroup Global Markets Inc.

  
 6 

 1.375% Notes due 2014 

 

			
		
	Issuer:	  	Texas Instruments Incorporated (“TI”)
		
	Principal Amount:	  	$1,000,000,000
		
	Maturity:	  	May 15, 2014
		
	Coupon:	  	1.375%
		
	Price to Public:	  	99.875% of principal amount
		
	Interest Payment Dates:	  	May 15 and November 15, commencing November 15, 2011
		
	Day Count Convention:	  	30/360
		
	Proceeds (before expenses) to TI:	  	$996,250,000
		
	Benchmark Treasury:	  	1.000% due May 15, 2014
		
	Spread to Benchmark Treasury:	  	50 basis points
		
	Yield to Maturity:	  	1.418%
		
	Benchmark Treasury Yield:	  	0.918%
		
	Make-Whole Call:	  	At any time at a discount rate of Treasury plus 7.5 basis points
		
	Special Mandatory Redemption:	  	At 101%, if TI’s merger with National Semiconductor Corporation has not closed by April 30, 2012, or such earlier date as the merger agreement is terminated
		
	Trade Date:	  	May 16, 2011
		
	Settlement Date:	  	May 23, 2011 (T+5)
		
	Denominations:	  	$2,000 and multiples of $1,000 thereafter
		
	CUSIP/ISIN:	  	882508 AQ7 / US882508AQ73
		
	Ratings:	  	 Moody’s: A1
 S&P:
A+

		
	Joint Book-Running Managers:	  	 Morgan Stanley & Co. Incorporated
 J.P. Morgan Securities LLC
 Merrill Lynch, Pierce, Fenner & Smith Incorporated

Citigroup Global Markets Inc.

  
 7 

 2.375% Notes due 2016 

 

			
		
	Issuer:	  	Texas Instruments Incorporated (“TI”)
		
	Principal Amount:	  	$1,000,000,000
		
	Maturity:	  	May 16, 2016
		
	Coupon:	  	2.375%
		
	Price to Public:	  	99.893% of principal amount
		
	Interest Payment Dates:	  	May 15 and November 15, commencing November 15, 2011
		
	Day Count Convention:	  	30/360
		
	Proceeds (before expenses) to TI:	  	$995,430,000
		
	Benchmark Treasury:	  	2.000% due April 30, 2016
		
	Spread to Benchmark Treasury:	  	60 basis points
		
	Yield to Maturity:	  	2.398%
		
	Benchmark Treasury Yield:	  	1.798%
		
	Make-Whole Call:	  	At any time at a discount rate of Treasury plus 10 basis points
		
	Special Mandatory Redemption:	  	At 101%, if TI’s merger with National Semiconductor Corporation has not closed by April 30, 2012, or such earlier date as the merger agreement is terminated
		
	Trade Date:	  	May 16, 2011
		
	Settlement Date:	  	May 23, 2011 (T+5)
		
	Denominations:	  	$2,000 and multiples of $1,000 thereafter
		
	CUSIP/ISIN:	  	882508 AR5 / US882508AR56
		
	Ratings:	  	 Moody’s: A1
 S&P:
A+

		
	Joint Book-Running Managers:	  	 Morgan Stanley & Co. Incorporated
 J.P. Morgan Securities LLC
 Merrill Lynch, Pierce, Fenner & Smith Incorporated

Citigroup Global Markets Inc.

  
 8 

 A securities rating is not a recommendation to buy, sell or hold securities and may be subject to
revision or withdrawal at any time. 
 It is expected that delivery of the notes will be made against payment therefor on or about
May 23, 2011, which is the fifth business day following the date hereof (such settlement cycle being referred to as “T+5”). Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market
generally are required to settle in three business days unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on the date of pricing or the next succeeding business day will be required,
by virtue of the fact that the notes initially will settle in T+5, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement. Purchasers of the notes who wish to trade the notes on the date of pricing
should consult their own advisors. 
 The issuer has filed a registration statement (including a prospectus) and a prospectus supplement
with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents the
issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer
participating in the offering will arrange to send you the prospectus and prospectus supplement if you request it by calling Morgan Stanley & Co. Incorporated at 1-866-718-1649, J.P. Morgan Securities LLC at 1-212-834-4533, Merrill Lynch,
Pierce, Fenner & Smith Incorporated at 1-800-294-1322 or Citigroup Global Markets Inc. at 1-877-858-5407. 
 Any disclaimer or
other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email system.

  
 9 

 SCHEDULE II 
 TO UNDERWRITING AGREEMENT 
  

																	
	 Underwriter
	  	2013 Floating
Rate Notes	 	  	2013 Notes	 	  	2014 Notes	 	  	2016 Notes	 
	 Morgan Stanley & Co. Incorporated
	  	$	210,000,000	  	  	$	105,000,000	  	  	$	210,000,000	  	  	$	210,000,000	  
	 J.P. Morgan Securities LLC
	  	 	210,000,000	  	  	 	105,000,000	  	  	 	210,000,000	  	  	 	210,000,000	  
	 Merrill Lynch, Pierce, Fenner & Smith Incorporated
	  	 	142,000,000	  	  	 	71,000,000	  	  	 	142,000,000	  	  	 	142,000,000	  
	 Citigroup Global Markets Inc.
	  	 	56,000,000	  	  	 	28,000,000	  	  	 	56,000,000	  	  	 	56,000,000	  
	 BNP Paribas Securities Corp.
	  	 	110,000,000	  	  	 	55,000,000	  	  	 	110,000,000	  	  	 	110,000,000	  
	 Mitsubishi UFJ Securities (USA), Inc.
	  	 	110,000,000	  	  	 	55,000,000	  	  	 	110,000,000	  	  	 	110,000,000	  
	 Mizuho Securities USA Inc.
	  	 	110,000,000	  	  	 	55,000,000	  	  	 	110,000,000	  	  	 	110,000,000	  
	 Barclays Capital Inc.
	  	 	26,000,000	  	  	 	13,000,000	  	  	 	26,000,000	  	  	 	26,000,000	  
	 The Williams Capital Group, L.P.
	  	 	26,000,000	  	  	 	13,000,000	  	  	 	26,000,000	  	  	 	26,000,000	  
		  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 Total
	  	$	1,000,000,000	  	  	$	500,000,000	  	  	$	1,000,000,000	  	  	$	1,000,000,000	  
		  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 

  
 10 

 SCHEDULE III 
 TO UNDERWRITING AGREEMENT 
 See Schedule I 

  
 11 

 SCHEDULE IV 
 TO UNDERWRITING AGREEMENT 
 The only information that the Underwriters have
furnished to the Company in writing expressly for use in the Prospectus Supplement is: 
  

	 	1.	The third paragraph of text under the caption “Underwriters” in the Prospectus Supplement, concerning the terms offered by the Underwriters;

  

	 	2.	The third and fourth sentences of the paragraph of text under the sub-caption “Underwriters—New Issue of Notes” in the Prospectus Supplement, concerning
market making by the Underwriters; and 

  

	 	3.	The two paragraphs of text under the sub-caption “Underwriters—Price Stabilization and Short Positions” in the Prospectus Supplement, concerning short
sales, purchases to cover short positions and stabilizing purchases. 

  
 12 

 Texas Instruments Incorporated Underwriting Agreement 

Standard Provisions 
 May 16, 2011 
 From time to time, Texas Instruments Incorporated, a Delaware
corporation, may enter into one or more underwriting agreements that provide for the sale of designated securities to the several underwriters named therein. The standard provisions set forth herein may be incorporated by reference in any such
underwriting agreement (an “Underwriting Agreement”). The Underwriting Agreement, including the provisions incorporated therein by reference, is herein referred to as this “Agreement”. Unless otherwise defined herein,
terms defined in the Underwriting Agreement are used herein as therein defined. 
 From time to time in one or more offerings on
terms determined at the time of sale, the Company proposes to issue and sell (a) its common stock, $1.00 par value per share (the “Common Stock”), (b) its preferred stock, $25.00 par value per share (the “Preferred
Stock”), (c) certain of its debt securities (the “Debt Securities”) issuable under an indenture (the “Indenture”) to be entered into by the Company and U.S. Bank National Association, as trustee (the
“Trustee”), (d) warrants to purchase Common Stock, Preferred Stock or Debt Securities (“Warrants”), and (e) units consisting of Common Stock, Preferred Stock, Debt Securities or Warrants or any combination
thereof (“Units”). The Common Stock, Preferred Stock, Debt Securities, Warrants and Units are each referred to as “Securities” for the purposes of this Agreement. 

The Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement including
a prospectus relating to the Securities and has filed with, or transmitted for filing to, or shall promptly after the date of this Agreement file with or transmit for filing to, the Commission a prospectus supplement (the “Prospectus
Supplement”) specifically relating to the Securities listed on Schedule I hereto (the “Offered Securities”) pursuant to Rule 424 under the Securities Act of 1933, as amended (the “Securities Act”). The
term “Registration Statement” means the registration statement, including the exhibits thereto and any additional registration statement filed by the Company pursuant to Rule 462, as amended to the date of the Underwriting
Agreement, including the information, if any, deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A or Rule 430B under the Securities Act. The term “Base Prospectus” means the
prospectus included in the Registration Statement. The term “Prospectus” means the Base Prospectus together with the Prospectus Supplement or supplements specifically relating to the Offered Securities, as filed with, or transmitted
for filing to, the Commission pursuant to Rule 424. The term “preliminary prospectus” means a preliminary prospectus supplement specifically relating to the Offered Securities, together with the Base Prospectus. The term
“free writing prospectus” has the meaning set forth in Rule 405 under the Securities Act. The term “issuer free writing prospectus” has the meaning set forth in Rule 433 under the Securities Act. The term
“Time of Sale Prospectus” means the Base Prospectus and preliminary prospectus, if any, together with any additional documents or other information identified in Schedule III to the Underwriting Agreement. As used herein, the terms
“Registration Statement,” “Base Prospectus,” “Prospectus,” 

  
 13 

 
“preliminary prospectus” and “Time of Sale Prospectus” shall include in each case the documents, if any, incorporated by reference therein. The terms “supplement,”
“amendment” and “amend” as used herein shall include all documents deemed to be incorporated by reference in the Prospectus that are filed subsequent to the date of the Base Prospectus by the Company with the Commission pursuant
to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As used herein, the term “Applicable Time” means the time and date set forth in the Underwriting Agreement or such other time as agreed in
writing by the Company and the Manager. 
 I. 
 The Company is advised by the Manager that the Underwriters propose to make a public offering of their respective portions of the Offered Securities as soon after this Agreement is entered into as in the
Manager’s judgment is advisable. The terms of the public offering of the Offered Securities are set forth in the Prospectus. 
 II. 
 Payment for the Offered Securities shall be made to the Company by Federal
funds wire transfer at the time and place set forth in the Underwriting Agreement, upon delivery to the Manager for the respective accounts of the several Underwriters of the Offered Securities registered in such names and in such denominations as
the Manager shall request in writing by the time specified in the Underwriting Agreement. The time and date of such payment and delivery with respect to the Offered Securities are herein referred to as the Closing Date. 

III. 
 The
several obligations of the Underwriters hereunder are subject to the following conditions: 
 (a) No stop order
suspending the effectiveness of the Registration Statement shall be in effect, and no proceedings for such purpose shall be pending before or threatened by the Commission and there shall have been no material adverse change (not in the ordinary
course of business), in the condition of the Company and its consolidated subsidiaries, taken as a whole, from that set forth in or contemplated by the Time of Sale Prospectus; and the Manager shall have received, on the Closing Date, a certificate,
dated the Closing Date and signed by an executive officer of the Company, to the foregoing effect. Such certificate will also provide (i) that the representations and warranties of the Company contained herein are true and correct as of the
Closing Date and (ii) that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date. The officer making such certificate may rely upon the best
of his knowledge as to proceedings pending or threatened. 
 (b) The Manager shall have received on the Closing
Date an opinion of Joseph F. Hubach, Esq., Senior Vice President, Secretary and General Counsel of the Company (or another lawyer of the Company reasonably satisfactory to the Underwriters), dated the Closing Date, to the effect (as applicable)
that: 

  
 14 

 (i) the Company has been duly incorporated, is validly existing as a
corporation in good standing under the laws of the State of Delaware and has full corporate power and authority to own its properties and conduct its business as presently conducted; 

(ii) the Company is duly qualified to transact business and is in good standing in each other state of the United States,
wherein it owns or leases material property or conducts material business, which requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and
its subsidiaries, taken as a whole; 
 (iii) the Company has an authorized capitalization as set forth in the
Time of Sale Prospectus; 
 (iv) the Registration Statement is effective under the Securities Act, and, to the
best of such counsel’s knowledge, no proceedings for a stop order are pending or threatened by the Commission; 
 (v) the execution, delivery and performance of this Agreement and, as applicable, the Indenture, the Offered Securities, the Warrant Agreement and the Unit Agreement (each, a “Transaction
Document”) will not contravene any provision of applicable law or the certificate of incorporation or by-laws of the Company or, to the knowledge of such counsel, any agreement or other instrument binding upon the Company that is filed as
an exhibit to the Registration Statement or to any document incorporated by reference in the Time of Sale Prospectus, and no consent, approval or authorization of any governmental body or agency is required for the performance by the Company of its
obligations under this Agreement or the applicable Transaction Documents, if any, except such as are specified and have been obtained and such as may be required by the securities or Blue Sky laws of the various states in connection with the offer
and sale of the Offered Securities by the Underwriters; 
 (vi) after due inquiry, such counsel does not know of
any legal or governmental proceedings pending or threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject that are required to be described in the
Registration Statement or the Time of Sale Prospectus and are not so described or of any contract or other document that is required to be described in the Registration Statement or the Time of Sale Prospectus or to be filed as an exhibit to the
Registration Statement that is not described or filed as required; 
 (vii) (A) in the opinion of such counsel
each document filed pursuant to the Exchange Act and incorporated by reference in the Registration Statement and the Prospectus (except for the financial statements and financial schedules and other financial and statistical data included therein,
as to which 

  
 15 

 
such counsel need not express any opinion) appeared on its face to be appropriately responsive as of its filing date in all material respects to the requirements of the Exchange Act and the
applicable rules and regulations of the Commission thereunder, and (B) nothing has come to the attention of such counsel that causes such counsel to believe that, insofar as relevant to the offering of the Offered Securities (1) the
Registration Statement as of the date the Registration Statement or any amendment (or any part thereof) is considered to have become effective as to the Underwriters pursuant to Section 11(d) of the Securities Act and Rule 430B(f)
promulgated thereunder (except for the financial statements and financial schedules and other financial and statistical data included therein and except for that part of the Registration Statement that constitutes the Form T-1, as to which such
counsel need not express any belief), contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading or (2) the Registration
Statement or any amendment thereto (except for the financial statements and financial schedules and other financial and statistical data included therein and except for that part of the Registration Statement that constitutes the Form T-1, as
to which such counsel need not express any belief) as of the date of this Agreement contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not
misleading or (3) the Time of Sale Prospectus (except for the financial statements and financial schedules and other financial and statistical data included therein, as to which such counsel need not express any belief) as of the Applicable
Time contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or (4) the Prospectus
(except for the financial statements and financial schedules and other financial and statistical data included therein, as to which such counsel need not express any belief) at the date of the Underwriting Agreement or as amended or supplemented, if
applicable, as of the Closing Date contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 (c) The Manager shall have received on the Closing Date an opinion of Davis Polk & Wardwell LLP,
special outside counsel to the Company, dated the Closing Date, to the effect (as applicable) that: 
 (i) if
shares of Common Stock or Preferred Stock are Offered Securities, such shares have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable, and the
issuance of such shares will not be subject to any preemptive or similar rights; 
 (ii) if Debt Securities are
Offered Securities, (A) such Debt Securities have been duly authorized and, when executed and authenticated in 

  
 16 

 
accordance with the Indenture and delivered to and paid for by the Underwriters, will be valid and binding obligations of the Company enforceable in accordance with their terms, subject to
applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally, concepts of reasonableness and equitable principles of general applicability (collectively, the “Enforceability Exceptions”),
(B) the Indenture has been duly authorized, executed and delivered by the Company and is a valid and binding agreement of the Company enforceable in accordance with its terms, subject to the Enforceability Exceptions, and (C) the Indenture
has been duly qualified under the Trust Indenture Act of 1939; 
 (iii) if Warrants are Offered Securities,
(A) such Warrants have been duly authorized and, when executed and delivered in accordance with the provisions of the Warrant Agreement and delivered to and paid for by the Underwriters in accordance with the terms of this Agreement, such
Warrants will be valid and binding obligations of the Company, enforceable in accordance with their terms, subject to the Enforceability Exceptions and (B) the Warrant Agreement has been duly authorized, executed and delivered by, and is a
valid and binding agreement of, the Company, enforceable in accordance with its terms, subject to the Enforceability Exceptions; 
 (iv) if Units are Offered Securities, (A) such Units have been duly authorized and, when executed and delivered in accordance with the provisions of the Unit Agreement and delivered to and paid for
by the Underwriters in accordance with the terms of this Agreement, such Units will be valid and binding obligations of the Company, enforceable in accordance with their terms, subject to the Enforceability Exceptions and (B) the Unit Agreement
has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, subject to the Enforceability Exceptions; 

(v) this Agreement has been duly authorized, executed and delivered by the Company; 

(vi) the Offered Securities conform in all material respects to the description thereof contained in the Time of Sale
Prospectus, as then amended or supplemented, if applicable, under the captions “Description of Capital Stock,” “Description of Debt Securities,” “Description of Warrants,” and “Description of Units,” as
applicable; 
 (vii) the statements in the Time of Sale Prospectus under “Certain U.S. Tax
Considerations” and “Underwriting” relating to legal matters fairly summarize in all material respects such legal matters; 
 (viii) in the case of Offered Securities that are convertible into or exercisable or exchangeable for other Securities (the “Underlying

  
 17 

 
Securities”), the Underlying Securities have been duly authorized and reserved for issuance; 
 (ix) when the Underlying Securities are issued upon conversion, exercise or exchange of the Offered Securities in accordance with the terms of the Offered Securities or any applicable Transaction
Document, such Underlying Securities will be validly issued, fully paid and non-assessable and will not be subject to any preemptive or other right to subscribe for or purchase such Underlying Securities; 

(x) the Company is not, and after giving effect to the distribution of the Securities and the application of the proceeds
thereof as described in each of the Registration Statement, Time of Sale Information and the Prospectus, the Company will not, be required to register as an “investment company” as such term is defined in the Investment Company Act of
1940, as amended; and 
 (xi) (A) in the opinion of such counsel the Registration Statement and the Prospectus
(except for the financial statements and financial schedules and other financial and statistical data included therein and except for that part of the Registration Statement that constitutes the Form T-1, as to which such counsel need not
express any opinion) appear on their face to be appropriately responsive in all material respects to the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder, and (B) nothing has come to the
attention of such counsel that causes such counsel to believe that, insofar as relevant to the offering of the Offered Securities (1) the Registration Statement as of the date the Registration Statement or any amendment (or any part thereof) is
considered to have become effective as to the Underwriters pursuant to Section 11(d) of the Securities Act and Rule 430B(f) promulgated thereunder (except for the financial statements and financial schedules and other financial and
statistical data included therein and except for that part of the Registration Statement that constitutes the Form T-1, as to which such counsel need not express any belief), contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary to make the statements therein not misleading or (2) the Registration Statement or any amendment thereto (except for the financial statements and financial schedules and other financial
and statistical data included therein and except for that part of the Registration Statement that constitutes the Form T-1, as to which such counsel need not express any belief) as of the date of this Agreement contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading or (3) the Time of Sale Prospectus (except for the financial statements and financial schedules and
other financial and statistical data included therein, as to which such counsel need not express any belief) as of the Applicable Time contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which 

  
 18 

 
they were made, not misleading or (4) the Prospectus (except for the financial statements and financial schedules and other financial and statistical data included therein, as to which such
counsel need not express any belief) at the date of the Underwriting Agreement or as amended or supplemented, if applicable, as of the Closing Date contained or contains any untrue statement of a material fact or omits to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 (d) The Manager shall have received on the Closing Date an opinion of its own counsel, in a form acceptable to the Manager, dated the Closing Date. 

It is understood that Joseph F. Hubach, Esq. may rely as to all matters relating to the laws of the State of New York upon the opinion of
Davis Polk & Wardwell LLP. 
 With respect to the matters set forth in (b)(vii) and (c)(xi) above, Joseph F.
Hubach, Esq., and Davis Polk & Wardwell LLP may state that their belief is based upon participation by them in the preparation of the Registration Statement (excluding, in the case of Davis Polk & Wardwell LLP, any documents
incorporated by reference therein), the Time of Sale Prospectus, and the Prospectus (as amended or supplemented) and review and discussion of the contents thereof (including any such incorporated documents), but is without independent check or
verification, except as specified. 
 (e) The Manager shall have received on the date hereof and on the Closing
Date a letter dated such date, in form and substance satisfactory to the Manager, from the Company’s independent public accountants, containing statements and information of the type ordinarily included in accountants’ “comfort
letters” to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus. 

(f) Subsequent to the Applicable Time and prior to the Closing Date, there shall not have occurred any downgrading, nor
shall any notice have been given of (i) any intended or potential downgrading or (ii) any review or possible change that, in the Manager’s opinion, indicates an intended or potential downgrading in the rating accorded any of the
Company’s securities by any “nationally recognized statistical rating organization,” as such term is used in Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act, that, in the Manager’s judgment, is material and adverse. 

(g) There shall not have occurred any change, or any event that is reasonably likely to cause a change, in the condition
of the Company and its subsidiaries, taken as a whole, from that set forth in or contemplated in the Time of Sale Prospectus as of the date of this Agreement, that, in the Manager’s judgment, is material and adverse and that makes it, in the
Manager’s judgment, impracticable to market the Offered Securities on the terms, in the manner and substantially at the price contemplated in the Time of Sale Prospectus. 

  
 19 

 IV. 
 In further consideration of the agreements of the Underwriters contained in this Agreement, the Company covenants as follows: 

(a) To furnish the Manager, without charge, one copy of the Registration Statement, including exhibits and materials, if
any, incorporated by reference therein, and, during the period mentioned in paragraph (f) below, as many copies of the Time of Sale Prospectus, the Prospectus, any documents incorporated by reference therein and any supplements and amendments
thereto as the Manager may reasonably request. 
 (b) Before amending or supplementing the Registration
Statement, the Time of Sale Prospectus or the Prospectus with respect to the Offered Securities, to furnish the Manager a copy of each such proposed amendment or supplement and will not file any such proposed amendment or supplement to which the
Manager reasonably objects unless, in the Company’s good faith judgment, the Company is required by law or regulation to make such filing. 
 (c) Before filing, using or referring to any free writing prospectus relating to the Offered Securities, to furnish the Manager a copy of each such free writing prospectus. 

(d) Not to take any action that would result in an Underwriter being required to file with the Commission pursuant to
Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder. 

(e) If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Securities at a time when the
Prospectus is not yet available to prospective purchasers and any event shall occur as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances
existing at the time, not misleading, or if any event shall occur as a result of which any free writing prospectus included as part of the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file,
the Company shall forthwith prepare and furnish, at its expense, to the Underwriters and to the dealers (whose names and addresses the Manager will furnish to the Company), either amendments or supplements to the Time of Sale Prospectus so that the
statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances existing at the time, be misleading or so that any free writing prospectus which is included as part of the Time of Sale Prospectus,
as amended or supplemented, will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law. 

(f) If, during such period after the first date of the public offering of the Offered Securities as in the opinion of
counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is required 

  
 20 

 
by law to be delivered in connection with sales by an Underwriter or dealer (the “Prospectus Delivery Period”), any event shall occur or condition exist as a result of which it
is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is delivered
to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own
expense, to the Underwriters and to the dealers (whose names and addresses the Manager will furnish to the Company) to which Securities may have been sold by the Manager on behalf of the Underwriters and to any other dealers upon request, either
amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under
the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. 
 (g) To endeavor to qualify the Offered Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Manager shall reasonably request and to pay all expenses (including
fees and disbursements of counsel) in connection with such qualification. 
 (h) To make generally available to
the Company’s security holders as soon as practicable an earning statement covering a twelve month period beginning after the date of this Agreement, which shall satisfy the provisions of Section 11(a) of the Securities Act and the
applicable rules and regulations thereunder; it being intended that the Company will satisfy the foregoing obligations by making available in the manner provided for by Rule 158 of the Securities Act copies of its annual report on Form 10-K and its
current reports on Form 10-Q. 
 (i) If Debt Securities are Offered Securities, during the period beginning on
the date of this Agreement and continuing to and including the Closing Date, not to offer, sell, contract to sell or otherwise dispose of any debt securities of the Company substantially similar to the Offered Securities (other than (i) the
Offered Securities or (ii) commercial paper issued in the ordinary course of business) without the prior written consent of the Manager. 
 (j) Upon the request of the Manager, to prepare a final term sheet relating to the offering of the Offered Securities, containing only information that describes the final terms of the Offered Securities
or the offering in a form consented to by the Manager, and to file such final term sheet within the period required by Rule 433(d)(5)(ii) under the Securities Act following the date the final terms have been established for the offering of the
Offered Securities. 
 (k) To pay the registration fees for this offering within the time period required by Rule
456(b)(1)(i) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date. 

  
 21 

 (l) Whether or not the transactions contemplated by this Agreement are
consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization,
issuance, sale, preparation and delivery of the Securities and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary
Prospectus, any Issuer Free Writing Prospectus, any Time of Sale Information and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the costs of reproducing and distributing each of
the Transaction Documents; (iv) the fees and expenses of the Company’s counsel and independent accountants; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for
investment of the Securities under the laws of such jurisdictions as the Manager may reasonably request and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the
Underwriters); (vi) any fees charged by rating agencies for rating the Securities; (vii) the fees and expenses of the Trustee and any paying agent (including related fees and expenses of any counsel to such parties); (viii) all
expenses and application fees incurred in connection with any filing with, and clearance of any offering by, the National Association of Securities Dealers, Inc.; and (ix) all expenses incurred by the Company in connection with any “road
show” presentation to potential investors. 
 (m) If this Agreement shall be terminated by the Underwriters,
or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this
Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably
incurred by such Underwriters in connection with this Agreement or the offering of the Securities contemplated hereby. 
 (n) During the Prospectus Delivery Period, to notify the Manager promptly in writing (i) when any amendment to the Registration Statement has been filed or becomes effective; (ii) when any
supplement to the Prospectus or any amendment to the Prospectus or any Issuer Free Writing Prospectus has been filed; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the
Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or. any other request by the Commission for any additional information; (iv) of the issuance by the Commission of any order suspending the
effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus or the Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act;
(v) of the occurrence of any event within the Prospectus Delivery Period as a result of which the Prospectus, the Time of Sale Information or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement
of a material fact or omit to state a material fact required to be stated therein 

  
 22 

 
or necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Time of Sale Information or any such Issuer Free Writing Prospectus is
delivered to a purchaser, not misleading; (vi) of the receipt by the Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the
Securities Act and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such
purpose; and the Company will use its commercially reasonable efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus or the
Prospectus or suspending any such qualification of the Securities and, if any such order is issued, will use its commercially reasonable efforts to obtain as soon as possible the withdrawal thereof. 

V. 
 The Company
represents and warrants to each Underwriter as of the date of the Underwriting Agreement that: 
 (a) The
Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or threatened by the Commission. The Company is a well-known
seasoned issuer (as defined in Rule 405 under the Securities Act) eligible to use the Registration Statement as an automatic shelf registration statement and the Company has not received notice that the Commission objects to the use of the
Registration Statement as an automatic shelf registration statement. 
 (b) Each document, if any, filed or to be
filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus or the Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the
Commission thereunder, (i) each part of the Registration Statement, when such part became effective, did not contain, and each such part, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) the Registration Statement as of the date hereof does not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii) the Registration Statement and the Prospectus comply, and as amended or supplemented, if applicable, will comply in all
material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iv) the Time of Sale Prospectus does not, and at the time of each sale of the Securities in connection with the offering when the
Prospectus is not yet available to prospective purchasers, the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, 

  
 23 

 
(v) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (vi) the Prospectus does not contain and, at the date of the Underwriting Agreement or as amended or supplemented, if
applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the
representations and warranties set forth in this paragraph do not apply to (A) statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Manager expressly for use therein or (B) that part of the Registration Statement that constitutes the Statement of Eligibility (Form T-1) under the Trust Indenture Act of the Trustee.

 (c) The Company is not an “ineligible issuer” in connection with the offering pursuant to
Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the
requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that
was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except for the
free writing prospectuses, if any, identified in Schedule I hereto forming part of the Time of Sale Prospectus, and electronic road shows, if any, each furnished to the Manager before first use, the Company has not prepared, used or referred to, and
will not, without the Manager’s prior consent, prepare, use or refer to, any free writing prospectus. 
 (d)
the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the State of Delaware and has full corporate power and authority to own its properties and conduct its business as presently conducted
and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so
qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
 (e) If shares of Common Stock or Preferred Stock are Offered Securities, such shares have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be
validly issued, fully paid and non-assessable, and the issuance of such shares will not be subject to any preemptive or similar rights. 
 (f) If Debt Securities are the Offered Securities, (i) such Debt Securities have been duly authorized and, when executed and authenticated in accordance with the provisions of the Indenture and
delivered to and paid for by the Underwriters in 

  
 24 

 
accordance with the terms of this Agreement, will be valid and binding obligations of the Company, in each case enforceable in accordance with their respective terms, subject to the
Enforceability Exceptions, and will be entitled to the benefits of the Indenture and (ii) the Indenture has been duly qualified under the Trust Indenture Act and has been duly authorized, executed and delivered by, and is a valid and binding
agreement of, the Company, enforceable in accordance with its terms, subject to the Enforceability Exceptions. 

(g) If Warrants are Offered Securities, (i) such Warrants have been duly authorized and, when executed and delivered
in accordance with the provisions of the Warrant Agreement and delivered to and paid for by the Underwriters in accordance with the terms of this Agreement, such Warrants will be valid and binding obligations of the Company, enforceable in
accordance with their terms, subject to the Enforceability Exceptions and (ii) the Warrant Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its
terms, subject to the Enforceability Exceptions. 
 (h) If Units are Offered Securities, (i) such Units have
been duly authorized and, when executed and delivered in accordance with the provisions of the Unit Agreement and delivered to and paid for by the Underwriters in accordance with the terms of this Agreement, such Units will be valid and binding
obligations of the Company, enforceable in accordance with their terms, subject to the Enforceability Exceptions and (ii) the Unit Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the
Company, enforceable in accordance with its terms, subject to the Enforceability Exceptions. 
 (i) This
Agreement has been duly authorized, executed and delivered by the Company. 
 (j) The Company is not in violation
of its charter or by-laws. The Company is not (1) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition
contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company is subject; or (2) in
violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (1) and (2) above, for any such default or violation that would
not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
 (k) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement and, as applicable, each other Transaction Document will not contravene
(i) any provision of applicable law, (ii) the certificate of incorporation or by-laws of the Company, (iii) any agreement or other instrument binding upon the Company or any of its subsidiaries, or (iv) any judgment, order or
decree of any governmental body, agency or court having jurisdiction over the 

  
 25 

 
Company or any subsidiary of the Company except, in the case of clauses (i), (iii) and (iv) above, as would not, individually or in the aggregate, reasonably be expected to have a
material adverse effect on the Company and its subsidiaries, taken as a whole. 
 (l) No consent, approval,
authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under this Agreement or the applicable Transaction Documents, except such as may be required by the
securities or Blue Sky laws of the various states in connection with the offer and sale of the Offered Securities. 
 (m) There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or
operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus. 
 (n) There are no legal or governmental proceedings pending or threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its
subsidiaries is subject other than proceedings described in the Time of Sale Prospectus and proceedings that would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries,
taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or the applicable Transaction Documents or to consummate the transactions contemplated by the Time of Sale Prospectus. 

(o) Each preliminary prospectus filed as part of the registration statement as originally filed or as part of any
amendment thereto, or filed pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder. 

(p) The Company is not, and after giving effect to the offering and sale of the Offered Securities and the application of
the proceeds thereof as described in the Time of Sale Prospectus will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended. 

VI. 
 The
Company agrees to indemnify and hold harmless each Underwriter and each person, if any, who controls each Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and
all losses, claims, damages and liabilities (including the reasonable fees and expenses of counsel in connection with any governmental or regulatory investigation or proceeding) caused by any untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company
information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, or the Prospectus or any amendment or supplement 

  
 26 

 
thereto, or caused by any omission or alleged omission to state therein a material fact necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or
liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information furnished to the Company in writing by such Underwriter through the Manager expressly for use therein. 

Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the
Registration Statement and each person, if any, who controls the Company to the same extent as the foregoing indemnity from the Company to each Underwriter, but only with reference to information relating to such Underwriter furnished to the Company
in writing by such Underwriter expressly for use in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus or the Prospectus or any amendment or supplement
thereto. 
 In case any proceeding (including any governmental investigation) shall be instituted involving any person in
respect of which indemnity may be sought pursuant to either of the two preceding paragraphs, such person (the “indemnified party”) shall promptly notify the person against whom such indemnity may be sought (the “indemnifying
party”) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may
designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel
shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any
impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the
indemnifying party shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate firm (in addition to any local counsel) for all such
indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Manager in the case of parties indemnified pursuant to the second preceding paragraph and by the
Company in the case of parties indemnified pursuant to the first preceding paragraph. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent but, if settled with such consent or if there
be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent
of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such
settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. 

  
 27 

 If the indemnification provided for in this Article VI under the first or second paragraphs
hereof is unavailable in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the
offering of the Offered Securities or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above
but also the relative fault of the Company on the one hand and of the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other in connection with the offering of the Offered Securities shall be deemed to be in the same proportion as the net proceeds from the
offering of such Offered Securities (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters in respect thereof, in each case as set forth in the table on the cover of
the Prospectus. The relative fault of the Company on the one hand and of the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

 The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Article VI
were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph. The amount paid or payable by an indemnified party as a
result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Article VI, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the
Offered Securities underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or
omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The Underwriters’ obligations to contribute pursuant to this Article VI are several, in proportion to the respective amounts of Offered Securities purchased by each of such Underwriters, and not joint. 

The indemnity and contribution agreements contained in this Article VI and the representations and warranties of the Company in this
Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Underwriter or on behalf of any Underwriter or any

  
 28 

 
person controlling any Underwriter or by or on behalf of the Company, its directors or officers or any person controlling the Company and (iii) acceptance of and payment for any of the
Offered Securities. 
 VII. 
 In further consideration of the agreements of the Company herein contained, each Underwriter severally covenants as follows: 

(a) Not to take any action that would result in the Company being required to file with the Commission under
Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter. 

(b) Not to use, refer to or distribute any free writing prospectus except (i) a free writing prospectus that
(A) is not an issuer free writing prospectus and (B) contains only information describing the preliminary terms of the Offered Securities or the offering thereof, which information is limited to the categories of terms referenced on
Schedule I to the Underwriting Agreement or otherwise permitted under Rule 134 of the Securities Act, (ii) a free writing prospectus as shall be agreed in writing with the Company that is not distributed, used or referred to by such
Underwriter in a manner reasonably designed to lead to its broad unrestricted dissemination (unless the Company consents in writing to such dissemination) or (iii) a free writing prospectus identified in Schedule III to the Underwriting
Agreement as forming part of the Time of Sale Prospectus. 
 VIII. 

This Agreement shall be subject to termination in the Manager’s absolute discretion, by notice given to the Company, if
(a) after the Applicable Time and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on or by, as the case may be, any of the New York Stock Exchange or the NASDAQ Global Market,
(ii) trading of any securities of the Company shall have been suspended on the New York Stock Exchange or in the U.S. over-the-counter market, (iii) a general moratorium on commercial banking activities in New York shall have been declared
by either Federal or New York State authorities, or (iv) there shall have occurred any outbreak or escalation of hostilities or a severe deterioration in U.S. financial markets or any other calamity or crisis that is material and adverse and
(b) in the case of any of the events specified in clause (a)(iv), such event singly or together with any other such event makes it, in the Manager’s judgment, impracticable to market the Offered Securities on the terms and in the manner
contemplated in the Time of Sale Prospectus and this Agreement. Any such termination of this Agreement shall be without liability on the part of any Manager or on the part of the Company except as stated in Article IX. 

IX. 
 If on the
Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase on such date, and the 

  
 29 

 
aggregate amount of Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate amount of the Offered
Securities to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the amount of Offered Securities set forth opposite their respective names in the Underwriting Agreement bears to the aggregate
amount of Offered Securities set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as the Manager may specify, to purchase the Offered Securities which such defaulting Underwriter or Underwriters agreed
but failed or refused to purchase on such date; provided that in no event shall the amount of Offered Securities that any Underwriter has agreed to purchase pursuant to the Underwriting Agreement be increased pursuant to this Article IX by an amount
in excess of one-ninth of such amount of Offered Securities without the written consent of such Underwriter. If on the Closing Date any Underwriter or Underwriters shall fail or refuse to purchase Offered Securities and the aggregate amount of
Offered Securities with respect to which such default occurs is more than one-tenth of the aggregate amount of Offered Securities to be purchased on such date, and arrangements satisfactory to the Underwriters and the Company for the purchase of
such Offered Securities are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter or the Company. In any such case either the Underwriters or the Company shall
have the right to postpone the Closing Date but in no event for longer than seven days, in order that the required changes, if any, in the Registration Statement and in the Prospectus or in any other documents or arrangements may be effected. Any
action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. 
 If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this
Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement, with respect to themselves,
severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with the Offered Securities. 

The Company acknowledges and agrees that the Underwriters are acting solely in the capacity of an arm’s length contractual
counterparty to the Company with respect to the offering of Offered Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or
any other person. Additionally, none of the Underwriters is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction with respect to the offering of Offered Securities
contemplated hereby. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have
no responsibility or liability to the Company with respect thereto. Any review by the Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the
Underwriters and shall not be on behalf of the Company. 

  
 30 

 This Agreement shall inure to the benefit of and be binding upon the parties hereto and
their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section VI hereof. Nothing in this Agreement is intended or shall be construed to give
any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Underwriter shall be deemed to be a successor merely by reason of such
purchase. 
 The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and
the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall
remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters. 
 This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 

THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 

  
 31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]